Awani Review

Complete News World

BioNTech will conduct trial campaigns in the UK

Frankfurt (awp/afp) – BioNtech, the German laboratory that developed one of the innovative vaccines against Covid-19, has announced that it will conduct clinical trials in Great Britain of a cancer treatment based on the same RNA technology messenger (mRNA). Friday.

The goal is to treat 10,000 patients with personalized mRNA-based cancer immunotherapies by 2030, BioEntech said in a statement.

The project is part of a deal with the UK government that includes “anti-cancer therapies, infectious disease vaccines and expanding BioNTech’s presence in the UK,” the report said.

The German lab, one of the pioneers in mRNA development, will open a new research and development center of around 70 people in Cambridge and set up a regional headquarters in London.

“Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for more than 20 years,” BioNTech CEO and co-founder Ugur Sahin said in the statement.

The company, which established itself on the international stage by discovering one of the first vaccines against Covid-19 developed by the American Pfizer, is involved in the development of new vaccines and treatments, particularly for cancer, malaria, shingles. , Tuberculosis.

“This agreement means that cancer patients will have early access to trials investigating personalized messenger RNA therapies,” the UK Department of Health said in a separate statement.

The amount of investment linked to this partnership was not disclosed.

The first phase, described by the British Ministry of Health, will identify “large numbers” of cancer patients who will be eligible for trials and explore potential vaccines for “multiple types of cancer”.

See also  Pouchitis Epidemiology Forecast, 2032: USA, Germany, Spain, Italy, France, United Kingdom and Japan - Focus on 7MM

Trials could begin in fall 2023.